Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

SIMPLE SUMMARY: For decades, there has been no globally accepted neoadjuvant or adjuvant therapy in resectable biliary tract cancer. Based on the results of the BILCAP trial, adjuvant capecitabine has been widely regarded as standard adjuvant therapy. Focusing on the management of resectable biliary...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Shin, Sang Hyun, Park, Joon-Oh, Kim, Kyu-Pyo, Jeong, Jae Ho, Ryoo, Baek-Yeol, Lee, Woohyung, Song, Ki-Byung, Hwang, Dae-Wook, Park, Jin-hong, Lee, Jae Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037230/
https://www.ncbi.nlm.nih.gov/pubmed/33916008
http://dx.doi.org/10.3390/cancers13071647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037230/
https://www.ncbi.nlm.nih.gov/pubmed/33916008
http://dx.doi.org/10.3390/cancers13071647

Ejemplares similares